Evidence map›Paper›PMID 24023603›Full record

ArticleMaedica2013

Role of leptin in autoimmune diseases.

Manole Cojocaru, Inimioara Mihaela Cojocaru, Isabela Siloşi, Suzana Rogoz

Open access · greenAbstract read
In one paragraph

Article in Maedica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Obesity and Risk for Lymphoma: Possible Role of Leptin.International journal of molecular sciences · 2022
    Review
  5. Review
  6. Review
  7. Toll-Like Receptors-2 and -4 in Graves' Disease-Key Players or Bystanders?International journal of molecular sciences · 2019
    Article
  8. Article
  9. Review
  10. Article
  11. Psychoneuroimmunoendocrinology: clinical implications.The World Allergy Organization journal · 2017
    Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Manole Cojocaru"Titu Maiorescu" University, Faculty of Medicine, Department of Physiology, "Dr. Ion Stoia" Center for Rheumatic Diseases, Bucharest, Romania.
Inimioara Mihaela Cojocaru
Isabela Siloşi
Suzana Rogoz
Titu Maiorescu University · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leptin represents a link between metabolism, nutritional status, and immune responses. Leptin is important for optimal functioning of the immune system. Leptin is a cytokine-like hormone with proinflammatory properties linked to autoimmune diseases. Moreover, there has been increasing evidence that leptin is involved in the pathogenesis of various autoimmune diseases. Leptin has been shown to enhance immune reactions in autoimmune diseases that are commonly associated with inflammatory responses. Both high and low levels of leptin might contribute to autoimmune diseases. Leptin has been explored as a potential target for therapeutic development in treating autoimmune diseases. In this review, we review here the most recent advances on the role of leptin in autoimmunity and in immune-rheumatological diseases.

Indexed as

autoimmune diseasesautoimmunityleptinpathophysiology

Identifiers

PMID24023603
PMCPMC3749767
OpenAlexW1938612376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.